Can we improve ABVD in Hodgkin's lymphoma?

摘要

Brentuximab vedotin is an antibody-drug conjugate-the antibody targets CD30 and is linked to the microtubule-disrupting agent auristatin. Although the unconjugated antibody had little, if any, activity in Hodgkin's lymphoma, when the conjugate was given as a single agent to patients with relapsed or refractory Hodgkin's lymphoma, 76 (75%, 95% Cl 64-9-82-6) of 102 patients achieved an objective response, and 35 (34%, 95% Cl 25-2-44-4) patients had complete remission.1 Brentuximab vedotin was registered with the European Medicines Agency and US Food and Drug Administration; the first conjugated antibody approved for use in lymphoma.